Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL003 in hypercholesterolemia and mixed dyslipidemia
NCT07278830Phase 2Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SAL003 in hypercholesterolemia and mixed dyslipidemia (4 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Low-Density Lipoprotein Cholesterol at 24 weeks. Started Jun 2023; status: completed.
02
Drugs
SAL003
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT07278830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07278830.